Patients (pts) were assigned to three cohorts: Cohort A (previously treated, anti‐PD1/PD‐L1 naïve UC and RCC), Cohort B (previously treated, anti‐PD1/PD‐L1 resistant UC and RCC pts), and Cohort C (PCA pts). Here, CD274 is linked to renal cell carcinoma.